Galcanezumab CONQUERs migraine prevention

Abstract

The introduction of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) or its receptor for migraine prevention has been a great success. In The Lancet Neurology, Wim M Mulleners and colleagues report data that complete findings from a series of randomised, controlled trials targeting CGRP in patients with migraine in whom previous prophylactic treatment attempts had been unsuccessful.1 These trials have shown that erenumab,2 fremanezumab,3 and, as reported now in this Article, galcanezumab1 can provide beneficial effects for these patients.